Proprietary radiosensitizing agents will be screened by Dartmouth University Medical School under a research agreement with the firm. Roberts will provide funding for the in vivo and in vitro screening. Two compounds are expected to go into Phase I clinicals in 1989. Roberts' lead radiosensitizer, etanidazole, is in Phase III trials in the U.S. and Europe. Roberts licensed etanidazole from the National Cancer Institute and is in agreements for the product with DuPont and Chemie Linz AG.
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.